柔肝健脾饮对乳腺癌患者外周血中粒细胞表面抗原CD13的影响

Effect of Rougan Jianpiyin on CD13 in peripheral granulocyte of patients with mammary cancer

目的观察柔肝健脾饮对乳腺癌患者外周血中粒细胞表面抗原CD13表达强度的影响。方法将32例乳腺癌患者随机分为A、B组,行联合化疗和中药辅助化疗交叉对照试验。第1个疗程:A组16例采用联合化疗方法 ,B组16例予化疗加柔肝健脾饮口服;第2个疗程:2组治疗方案进行互换,即A组在联合化疗的基础上给予柔肝健脾饮口服治疗,B组单纯采用联合化疗方法。2组均21d为1个疗程,2个疗程无间隔。各疗程结束时分别观察2组外周血中粒细胞表面抗原CD13表达、卡氏评分分值、体质量及生活质量问卷-Base(Base表)和生活质量问卷-Breast(Breast表)总分值情况,并于第2个疗程结束后进行疗效比较。结果柔肝健脾饮配合联合化疗降低外周血中粒细胞表面抗原CD13的阳性标记率、提高卡氏评分、降低Base表评分及Breast表评分的作用均优于单纯化疗法(P<0.05)。结论柔肝健脾饮能提高乳腺癌患者生活质量,同时降低外周血中粒细胞表面抗原CD13的阳性标记率。

Objective To observe the effect of Rougan Jianpiyin on CD13 in peripheral blood cells of pa- tients with mammary cancer. Methods 32 cases of mammary cancer were randomly divided into A and B groups. Cross controlled trial of only chemotherapy and combination of traditional medicine and chemotherapy were adapted to A and B groups. In the first course,only chemotherapy was adopted to A group （ n = 16）,combination of Rougan Jianpiyin and chemotherapy was adapted to B group （ n = 16）. In the second course,combination of Rougan Jianpiyin and chemotherapy was adopted to A group,only chemotherapy was adapted to B group. The course was 21 days in two groups. There was no interval between two courses. The expression of CD13,karnofsky score value,constitution questionnaire and quality of life questionnaire-base were analyzed and compared after every courses. Results Rougan Jianpiyin combined with chemotherapy can decrease the positive sign rate of CD13,questionnaire-base and questionnaire -breast,and increase karnofsky score value. The effect of combination of Rougan Jianpiyin and chemo-therapy was superior to that in chemotherapy. Conclusion Rougan Jianpiyin can improve the life quality of patients with mammary cancer,and decrease the positive sign rate of CD13.